---
title: "Rapamycin (Sirolimus) FAERS Safety Signals: Post-Market Data"
description: "FAERS reports are unverified and cannot estimate incidence. In Rapamune's kidney transplant trial, hypertriglyceridemia was 45% to 57% vs 23% on placebo."
url: https://healthrx.com/regulatory-rapamycin/safety-signals-faers
publisher: HealthRX.com
---


[Print or save as PDF](https://healthrx.com/printables/regulatory-rapamycin/safety-signals-faers?print=1)

Key numbers

- 45% to 57% Hypertriglyceridemia in sirolimus-treated kidney transplant patients (placebo: 23%) Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc), as cited Nov 7, 2026
- 0.7% to 3.2% Lymphoma or lymphoproliferative disease in sirolimus-treated renal transplant patients Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc), as cited Nov 7, 2026
- 48 weeks Length of the PEARL trial of low-dose compounded rapamycin in healthy older adults Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40188830/), as cited Nov 7, 2026

[See the public record for Sirolimus](https://healthrx.com/data/sirolimus)

HealthRX.com quick answer. FDA's public adverse-event dashboard does not show how often sirolimus causes a given harm: a report is unverified and may be incomplete or duplicated, it does not prove that sirolimus caused an event, and the reports cannot be used to estimate incidence [1]. The sirolimus adverse-reaction rates that can be quoted come from the Rapamune label's controlled trials, where hypertriglyceridemia occurred in 45% to 57% of sirolimus-treated kidney transplant patients versus 23% on placebo [2].

At a glance

- Approved uses / Kidney transplant rejection prophylaxis (age 13 and older) and lymphangioleiomyomatosis; no longevity indication [2]
- What the FDA adverse-event dashboard is / Reports submitted by pharmaceutical companies, health care professionals and consumers; FDA is implementing AEMS to consolidate reporting systems [1]
- Hypertriglyceridemia in the label's renal transplant trial / 45% on 2 mg a day, 57% on 5 mg a day, 23% on placebo [2]
- Hypercholesterolemia, same trial / 43%, 46%, 23% [2]
- Boxed warning / Immunosuppression; not recommended in liver or lung transplant patients [2]

## What the FDA dashboard and Sentinel cover

FDA's public adverse-event dashboard covers reports submitted by pharmaceutical companies, health care professionals and consumers, and FDA is implementing the Adverse Event Monitoring System (AEMS) to consolidate reporting systems across product categories [1]. FDA also runs Sentinel: the Sentinel Initiative began in 2008, and the full Sentinel System officially launched in February 2016, built on a multisite distributed database of partner organizations [3].

## The sirolimus numbers that do exist

In the placebo-controlled kidney transplant trial on the Rapamune label, 218 patients took sirolimus oral solution 2 mg a day, 208 took 5 mg a day and 124 took placebo, all with cyclosporine and corticosteroids, with reactions counted at 12 months or later [2]. The label's table reads:

- Hypertriglyceridemia: 45% at 2 mg, 57% at 5 mg, 23% on placebo [2]
- Hypercholesterolemia: 43%, 46%, 23% [2]
- Peripheral edema: 54%, 58%, 48% [2]
- Thrombocytopenia: 14%, 30%, 9% [2]
- Anemia: 23%, 33%, 21% [2]

## Signals the label already flags

- Interstitial lung disease and non-infectious pneumonitis are listed in the label's warnings and precautions [2].
- Impaired or delayed wound healing, including lymphocele and wound dehiscence, is a labeled risk, and lymphocele occurred significantly more often with sirolimus in a dose-related pattern [2]. The European product information lists slow wound healing among side effects affecting more than 1 in 10 people [4].
- Lymphoma and lymphoproliferative disease occurred in 0.7% to 3.2% of sirolimus-treated patients versus 0.6% to 0.8% of azathioprine and placebo controls in the two renal transplant studies [2].
- Stomatitis falls among reactions reported in 3% to under 20% of renal transplant patients, and heads the most common (20% or more) list in the LAM study [2].

## What the low-dose trials reported

PEARL gave 48 weeks of weekly 5 mg or 10 mg compounded [rapamycin](https://healthrx.com/products/rapamycin), or placebo, to healthy normally aging adults; adverse and serious adverse events were similar across groups and blood biomarkers stayed within normal ranges [5]. The earlier pilot randomized 25 generally healthy adults aged 70 to 95 to 1 mg daily rapamycin or placebo; 11 rapamycin participants and 14 placebo participants completed at least 8 weeks [6]. The immune-aging trial often cited alongside these tested everolimus (RAD001), a different mTOR inhibitor, and measured antibody response to influenza vaccine [7].

## Do the label rates apply to low-dose use?

The label rates above come from transplant and LAM dosing, not from the low intermittent doses used in longevity trials [2]. Compounded rapamycin is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [8].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, can FDA dashboard reports be used to estimate how often sirolimus causes a given harm?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Printable question sheet

Sirolimus and rapamycin safety signals visit sheet

Use this sheet before a visit about sirolimus or rapamycin. It helps you bring your medicine details, the label facts you read, and questions about side effect reports to your prescriber or pharmacist.

[Open the fill-in sheet](https://healthrx.com/printables/regulatory-rapamycin/safety-signals-faers) Fill it in, print it or save it as a PDF. No sign-up.

Questions worth asking

Choose the questions you want to keep What does the FDA adverse event dashboard show, and what does it not show? Which side effects are listed in the sirolimus label's trial tables? Does the sirolimus label warn about lung problems or wound healing? Do the label's transplant rates apply to the low doses used in longevity studies? Is compounded rapamycin checked by the FDA for safety and quality?

Frequently asked questions

Which side effects had the highest rates in the label's trials?

In the kidney transplant study, hypertriglyceridemia (45% at 2 mg a day, 57% at 5 mg a day, 23% on placebo), hypercholesterolemia (43%, 46%, 23%) and peripheral edema (54%, 58%, 48%) [2].

Does the sirolimus label warn about lung problems?

Yes. Interstitial lung disease and non-infectious pneumonitis appear in the label's warnings and precautions [2].

Is sirolimus approved for longevity?

No. The labeled uses are kidney transplant rejection prophylaxis in patients aged 13 and older and lymphangioleiomyomatosis [2].

References

Show all 8 references Hide references

1. [FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA](https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard).
2. U.S. National Library of Medicine, DailyMed. Rapamune sirolimus tablets and oral solution (Pfizer) prescribing information. [Rapamune sirolimus tablets and oral solution (Pfizer) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc)
3. [FDA's Sentinel Initiative | FDA](https://www.fda.gov/safety/fdas-sentinel-initiative).
4. [Rapamune | European Medicines Agency (EMA)](https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune).
5. Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, et al. [Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results](https://pubmed.ncbi.nlm.nih.gov/40188830/). Aging (Albany NY). 2025;17(4):908-936.
6. Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. [A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects](https://pubmed.ncbi.nlm.nih.gov/29408453/). Exp Gerontol. 2018;105:53-69.
7. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. [mTOR inhibition improves immune function in the elderly](https://pubmed.ncbi.nlm.nih.gov/25540326/). Sci Transl Med. 2014;6(268):268ra179.
8. [Compounding and the FDA: Questions and Answers | FDA](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers).

Next in this cluster

Related reading

- [sirolimus Rapamycin label updates](https://healthrx.com/regulatory-rapamycin/label-updates)
- [sirolimus Rapamycin legal challenges](https://healthrx.com/regulatory-rapamycin/legal-challenges)
- [sirolimus Rapamycin how to stop](https://healthrx.com/rapamycin/discontinuation-protocol)
- [sirolimus Rapamycin (Sirolimus) and Exercise: What You Need to Know](https://healthrx.com/lifestyle-rapamycin/exercise)
- [sirolimus Rapamycin cost](https://healthrx.com/reviews-rapamycin/cost-reports)
- [sirolimus Rapamycin reviews](https://healthrx.com/reviews-rapamycin/efficacy-reports)
- [sirolimus Rapamycin first 3 months](https://healthrx.com/reviews-rapamycin/first-3-months)
- [sirolimus Rapamycin (Sirolimus) Regret, Stopping, and Restarting](https://healthrx.com/reviews-rapamycin/regret-and-restart)
- [sirolimus Rapamycin reviews](https://healthrx.com/reviews-rapamycin/satisfaction-trends)
- [sirolimus Sirolimus side effects](https://healthrx.com/reviews-rapamycin/side-effect-reports)
- [sirolimus Rapamycin (Sirolimus) Switching Reports](https://healthrx.com/reviews-rapamycin/switching-reports)
- [sirolimus Sirolimus permanent side effects](https://healthrx.com/side-effects-v2-rapamycin/permanent-side-effects)
- [rapamycin sirolimus Rapamycin (Sirolimus) for Longevity](https://healthrx.com/longevity-rx/rapamycin-sirolimus)
- [sirolimus Rapamycin sirolimus progesterone HRT interaction](https://healthrx.com/interactions-rapamycin/with-hrt-progesterone)

![rapamycin FAERS safety signals: nurse discussing lab monitoring results with patient in clinic](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/regulatory-rapamycin/safety-signals-faers.webp)

Monitoring lipids and other labs matters because sirolimus can raise triglycerides, a signal the label already describes. Full rapamycin FAERS guide and sources at [healthrx.com/regulatory-rapamycin](https://healthrx.com/regulatory-rapamycin).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
